Best Polynucleotide Brands for Under-Eye Rejuvenation: Complete Clinical Comparison

The under-eye area (tear trough) is the most technically demanding region in aesthetic medicine. With skin only 0.5mm thick, a dense vascular network, and constant lymphatic movement, traditional hyaluronic acid (HA) fillers — while effective — carry inherent risks including the Tyndall effect (bluish discoloration), chronic edema, and visible lumps.

Polynucleotides (PN) and Polydeoxyribonucleotides (PDRN) have emerged as a revolutionary alternative for under-eye rejuvenation. Unlike HA fillers that physically fill the tear trough, polynucleotides work at the cellular level — binding to adenosine A2A receptors to stimulate fibroblast activity, thicken the dermis, improve microcirculation, and reduce dark circles caused by thin skin and vascular visibility. Crucially, polynucleotides carry zero risk of Tyndall effect, making them the safest injectable option for this delicate area.

This guide compares six of the most widely used and clinically validated polynucleotide brands specifically indicated or optimized for under-eye treatment: Nucleofill Eyes, Rejuran I, Ameela Eyes, Plinest Fast, Newest, and Vitaran PDRN. It focuses on formulation, periocular safety, mechanism of action, clinical efficacy, and real-world feedback from both practitioners and patients.

⚠️ IMPORTANT MEDICAL DISCLAIMER
Medical-grade polynucleotide products are classified as medical devices (or prescription medicines, depending on the jurisdiction). Periorbital injections must be performed only by appropriately qualified healthcare professionals with advanced knowledge of orbital anatomy. The under-eye area carries elevated risks including vascular occlusion (which can cause blindness). This article is for educational purposes and does not replace official product labeling, clinical training, or professional medical judgment.

📑 Table of Contents

1. Quick Comparison
2. Why Polynucleotides Are Ideal for the Under-Eye Area
3. How to Compare Polynucleotide Brands for Under-Eye Use
4. Leading Brands: Individual Profiles
5. Under-Eye Treatment Protocols
6. Safety Considerations and Periorbital Risk Management
7. Regulatory Status and Supply Chain Verification
8. Frequently Asked Questions (FAQ)
9. Conclusion

1. Quick Comparison

The following table provides a high-level overview of the leading polynucleotide brands used for under-eye rejuvenation. Always confirm the specific product variant and its local regulatory authorization for periorbital use.

↔ Scroll horizontally to view the full table

2. Why Polynucleotides Are Ideal for the Under-Eye Area

Unlike HA fillers, which physically occupy space, polynucleotides work by regenerating the tissue itself. This makes them uniquely suited for the periorbital region, where traditional fillers carry significant risks.

Key Advantages of Polynucleotides for Under-Eyes:

• Zero Tyndall Effect Risk: Unlike HA fillers, PN does not scatter light when placed superficially. No risk of bluish discoloration — a critical advantage in the thinnest skin on the body.
• No Chronic Edema: PN is not hydrophilic (does not attract water), eliminating the risk of persistent under-eye puffiness or “bags” that can occur with HA fillers.
• Dermal Thickening: PN stimulates fibroblasts to produce new collagen, physically thickening the under-eye skin and reducing the visibility of underlying blood vessels (a primary cause of dark circles).
• Improved Microcirculation: PDRN promotes angiogenesis, improving blood flow and reducing the appearance of vascular dark circles.
• Anti-Inflammatory Properties: PN reduces inflammation, making it ideal for patients with sensitive, reactive, or rosacea-prone periorbital skin.
• Natural-Looking Results: No risk of overfilling or “puffy” appearance. Results are subtle, progressive, and undetectable.

When HA Fillers Are Still Preferred:

Polynucleotides are not volumizers. For patients with deep, structural tear trough hollows requiring significant projection, HA fillers (like Teosyal Redensity 2 or Belotero Balance) may still be the first-line treatment. PN is ideal for patients with:

• Thin, crepey under-eye skin
• Dark circles due to vascular visibility or skin thinness
• Fine periorbital lines
• Mild to moderate tear troughs where skin quality improvement is the primary goal
• Patients who have experienced complications with HA fillers (Tyndall, edema, lumps)

3. How to Compare Polynucleotide Brands for Under-Eye Use

Not all PN products are suitable for the delicate periorbital area. Clinicians evaluate under-eye PN products based on:

1. 🧬 Molecular Weight: Lower molecular weight (like c-PDRN) penetrates thin periorbital skin more effectively and carries a lower risk of inflammatory reactions.
2. ⚗️ Purity and Endotoxin Levels: The under-eye area is highly sensitive. Ultra-pure formulations with low endotoxin levels minimize swelling and irritation.
3. 💧 Viscosity: Low-viscosity products integrate more smoothly into thin periorbital tissue without causing visible bumps or papules.
4. 🎯 Periorbital-Specific Formulation: Some brands offer variants specifically designed for the eye area (e.g., Nucleofill Eyes, Rejuran I, Ameela Eyes), with optimized concentration and injection protocols.
5. 🛡️ Safety Profile: Absence of cross-linking agents, minimal hydrophilicity, and rigorous sterilization processes.
6. 🌍 Regulatory Status: CE Mark (Europe), MFDS approval (South Korea), or local health authority clearance specifically for periorbital use.

4. Leading Brands: Individual Profiles

Editorial note: The following sections summarize product characteristics, clinical consensus, expert opinions, and real-world market feedback. They do not constitute a ranking of clinical superiority. Under-eye treatment requires exceptional anatomical knowledge and should only be performed by experienced practitioners.

1. Nucleofill Eyes (Promoitalia)

2. Rejuran I / Rejuran Healer I (PharmaResearch)

3. Ameela Eyes (Ameela Co., Ltd.)

4. Plinest Fast (Mastelli)

5. Newest (Newest S.r.l.)

6. Vitaran PDRN (Various Korean Manufacturers)

5. Under-Eye Treatment Protocols

Polynucleotides for under-eye rejuvenation are typically administered via manual intradermal injection using a fine-gauge needle (30G or 32G) or a blunt-tipped cannula (25G or 27G) for enhanced safety. The following table provides general guidelines, but individual protocols should be determined by a qualified practitioner.

↔ Scroll horizontally to view the full table

💡 Pro-Tip for Practitioners:

For under-eye PN treatment, many experts recommend using a blunt-tipped cannula (25G or 27G) rather than a sharp needle. The cannula significantly reduces the risk of vascular occlusion and bruising in the highly vascular periorbital area. The product is injected in small aliquots (0.05–0.1mL per injection point) in the superficial suborbicularis plane, avoiding the orbital septum.

6. Safety Considerations and Periorbital Risk Management

⚠️ CRITICAL SAFETY WARNING: PERIORBITAL VASCULAR OCCLUSION
The under-eye area carries elevated risk of vascular occlusion due to the dense vascular network surrounding the orbit (angular artery, infraorbital artery). Accidental injection into a blood vessel can cause tissue necrosis or, in rare cases, blindness. Practitioners must have extensive knowledge of periorbital anatomy, use appropriate injection techniques (cannula preferred, aspiration before injection, slow injection with low pressure), and have an emergency protocol in place. While polynucleotides cannot be dissolved with hyaluronidase (unlike HA fillers), their non-hydrophilic nature significantly reduces the risk of chronic complications.

Key Safety Considerations for Under-Eye PN Treatment:

• Vascular Occlusion: The periorbital region has a complex vascular network. Use of a blunt-tipped cannula significantly reduces this risk. Aspiration before injection is recommended, though not foolproof.
• Transient Papules: Intradermal injection of PN can cause small, mosquito-bite-like bumps that typically resolve within 12–24 hours. This is normal and expected.
• Infection Risk: Strict aseptic technique is mandatory. The skin must be thoroughly cleansed, and the injection device must be sterile and single-use.
• Post-Procedure Care: Patients must avoid sun exposure, harsh actives (retinoids, AHAs/BHAs), saunas, and heavy makeup for 24–48 hours post-treatment.
• Salmon Allergy: Although highly purified, patients with severe, anaphylactic seafood or salmon allergies should be screened carefully. Patch testing is recommended for high-risk individuals.

Contraindications:

• Active infection or skin disease in the treatment area
• Known allergy to any component of the product (including salmon/seafood allergies)
• History of severe allergic reactions or anaphylaxis
• Autoimmune disorders or immunosuppression
• Bleeding disorders or use of anticoagulants
• Unrealistic expectations or body dysmorphic disorder
• Pregnancy and breastfeeding

7. Regulatory Status and Supply Chain Verification

The polynucleotide market, particularly Korean brands like Rejuran and Vitaran, is heavily targeted by counterfeiters. For clinics and distributors, verifying the supply chain is a matter of patient safety and legal compliance.

1. Regulatory Approval: Ensure the product has a valid CE Mark (Europe), MFDS approval (South Korea), or equivalent local health authority approval. Note that many PN products are used off-label for under-eye treatment — verify practitioner experience.
2. Authorized Distributors: Purchase only directly from the manufacturer or their explicitly authorized national distributors.
3. Authentication Features: Check for holographic seals, unique QR codes, or scratch-off verification labels on the packaging (e.g., Rejuran’s official verification website).
4. Temperature Control: Most PN products require refrigerated storage (2–8°C). Verify that the supplier maintains proper cold-chain logistics.

Never purchase polynucleotides from unauthorized online marketplaces, social media sellers, or unverified third-party wholesalers. Counterfeit Rejuran, Nucleofill, and Korean PN products are among the most common fake products on the black market.

8. Frequently Asked Questions (FAQ)

❓ Which polynucleotide brand is the best for under-eyes?
There is no universally “best” brand — the optimal choice depends on the patient’s specific concerns, skin thickness, and the practitioner’s expertise. Nucleofill Eyes is specifically formulated for the periorbital area and is widely regarded as the gold standard for under-eye skin quality improvement. Rejuran I is the gold standard for dark circles and skin repair. Ameela Eyes offers a hybrid approach with immediate hydration. Plinest Fast is ideal for sensitive skin and zero downtime. For budget-conscious patients, Vitaran PDRN offers excellent value.

❓ Are polynucleotides safer than HA fillers for under-eyes?
Yes, in many ways. Polynucleotides carry zero risk of Tyndall effect (bluish discoloration) and zero risk of chronic edema (puffiness) — two of the most common complications with HA fillers in the under-eye area. However, unlike HA fillers, polynucleotides cannot be dissolved with hyaluronidase if complications occur. The choice depends on the patient’s anatomy, concerns, and risk tolerance.

❓ Can polynucleotides fix deep tear trough hollows?
No. Polynucleotides are not volumizers. They work by improving skin quality, thickening the dermis, and reducing dark circles — but they do not provide significant structural volume. For deep tear trough hollows, HA fillers (like Teosyal Redensity 2 or Belotero Balance) or surgical options (fat grafting, lower blepharoplasty) are more appropriate. Polynucleotides are ideal for patients with mild to moderate tear troughs where skin quality improvement is the primary goal.

❓ How long does it take to see results from under-eye polynucleotides?
Unlike HA fillers, polynucleotides work at the cellular level. Patients may notice improved hydration and a “brighter” appearance within a few days, but significant improvements in skin thickness, elasticity, and dark circles typically become visible 4–6 weeks after the first session, peaking after a full course of 2–4 treatments.

❓ Can polynucleotides be dissolved if I don’t like the results?
No. Polynucleotides cannot be dissolved with hyaluronidase. They are biocompatible and gradually metabolized by the body over 6–12 months. This makes proper product selection and injection technique critical. However, because PN works by regenerating tissue rather than physically filling space, the risk of “overcorrection” or unnatural results is extremely low.

❓ Are Korean polynucleotides (Rejuran I, Vitaran) as good as European brands?
Clinical data and practitioner feedback suggest that authentic, properly regulated Korean polynucleotides offer comparable safety and efficacy to premium Western brands for under-eye treatment. Rejuran I, in particular, has over two decades of clinical data and is considered the gold standard in Asia. The key is ensuring product authenticity through authorized supply chains.

❓ Is under-eye polynucleotide treatment painful?
Most patients report mild to moderate discomfort during under-eye polynucleotide injections. Topical numbing cream is routinely applied to maximize comfort. The under-eye area is sensitive, but most patients tolerate the procedure well. Some products (like Plinest Fast) are specifically formulated to be virtually painless.

❓ What is the downtime after under-eye polynucleotide treatment?
Most polynucleotide treatments have minimal downtime. Patients may experience mild swelling, redness, or small papules at injection sites, which typically resolve within 12–24 hours. Products like Plinest Fast and Rejuran I are particularly known for their minimal downtime, allowing patients to resume normal activities immediately after treatment.

❓ Can polynucleotides be combined with other under-eye treatments?
Yes, polynucleotides are highly synergistic. They can be combined with HA fillers (for patients who need both volume and skin quality improvement), microneedling, PRP (Platelet-Rich Plasma), or low-energy laser therapies. Many practitioners recommend a combination approach for comprehensive under-eye rejuvenation. However, timing and sequencing should be determined by a qualified professional.

9. Conclusion: Choosing a Polynucleotide for Under-Eyes Based on Evidence

Nucleofill Eyes, Rejuran I, Ameela Eyes, Plinest Fast, Newest, and Vitaran PDRN each offer distinct advantages for under-eye rejuvenation. The choice should be driven by the patient’s specific concerns (dark circles, fine lines, skin thinness, mild hollows), skin sensitivity, budget, and the practitioner’s expertise — not by marketing trends alone.

A reliable approach prioritizes:

• Matching the polynucleotide’s formulation and molecular weight to the patient’s specific periorbital concerns.
• Understanding that polynucleotides improve skin quality, not volume — they are not a substitute for HA fillers in deep tear troughs.
• Sourcing exclusively from authorized, traceable supply chains — especially for Korean-manufactured products.
• Ensuring the procedure is performed by a qualified, anatomically trained medical professional with extensive experience in periorbital injections.
• Proper patient selection and realistic expectation management.

For healthcare professionals and qualified buyers, the strongest decisions are supported by verifiable clinical data, rigorous safety protocols, and legitimate supply chains.

📚 Official Sources and Further Reading

1. PubMed – Polynucleotide Periorbital Studies – Peer-reviewed clinical studies on polynucleotide use in the periorbital area.
2. PubMed – PDRN for Dark Circles – Clinical research on PDRN efficacy for periorbital hyperpigmentation and skin thinning.
3. EUDAMED – European medical device regulatory verification for polynucleotide products.
4. MFDS (South Korea) – Korean Ministry of Food and Drug Safety for Rejuran and related product verification.
5. Promoitalia Official – Official product information for Nucleofill Eyes.

Editorial note: Medical device regulations, product formulations, and clinical guidelines can change. Review the latest official documentation and local regulatory updates before publication or clinical application.